A Randomized Double-Blind, Placebo-Controlled Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
Latest Information Update: 23 Jul 2024
At a glance
- Drugs SEL 212 (Primary)
- Indications Gout
- Focus Registrational; Therapeutic Use
- Acronyms DISSOLVE II
- Sponsors Selecta Biosciences
- 15 Jun 2024 Results of pooled analysis describing the combined efficacy and safety data for SEL-212 from the 6-month DISSOLVE-I & II studies, presented at the 25th Annual Congress of the European League Against Rheumatism
- 15 Nov 2023 Pooled analysis results of DISSOLVE I and II trials assessing Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment, were presented at the ACR Convergence 2023
- 17 Aug 2023 According to a Selecta Biosciences media release, the company to submit a BLA submission in the first half of 2024.